Nymox Pharmaceutical Corporation
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $-241.0K | $2.0M |
| FY2017 | — | $-1.3M | $851.0K |
| FY2018 | — | $7.0M | $7.9M |
| FY2019 | — | $3.4M | $5.2M |
| FY2020 | — | $2.1M | $3.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $-241.0K | $2.0M |
| FY2017 | — | $-1.3M | $851.0K |
| FY2018 | — | $7.0M | $7.9M |
| FY2019 | — | $3.4M | $5.2M |
| FY2020 | — | $2.1M | $3.6M |